๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-02-27

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (NCT02574728)

AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

๐Ÿ”ต Active, Not Recruiting Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Emory University

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.

Who can join: Review the eligibility criteria below.

Location: Phoenix Children's Hospital โ€” Phoenix, Arizona

Age range: 12 Months to 30 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (6 Sites)

  • Phoenix Children's Hospital โ€” Phoenix, Arizona
  • Nemours/Alfred I. duPont Hospital for Children โ€” Wilmington, Delaware
  • Children's Healthcare of Atlanta-Egleston โ€” Atlanta, Georgia
  • Children's Healthcare of Atlanta, Scottish Rite โ€” Atlanta, Georgia
  • Children's Mercy Hospital โ€” Kansas City, Missouri
  • University of Virginia Health System โ€” Charlottesville, Virginia

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Cancer clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—